Risk assessment and HbA1c measurement in Norwegian community pharmacies to identify people with undiagnosed type 2 diabetes - A feasibility study

PLoS One. 2018 Feb 23;13(2):e0191316. doi: 10.1371/journal.pone.0191316. eCollection 2018.

Abstract

Objectives: Determine the feasibility of using a diabetes risk assessment tool followed by HbA1c-measurement in a community-pharmacy setting in Norway.

Methods: In this longitudinal study two pharmacists in each of three community pharmacies were trained to perform risk assessments, HbA1c-measurements and counselling. Pharmacy customers who were > 18 years old and could understand and speak Norwegian or English were recruited in the pharmacies during a two-months-period. Information about the service was presented in local newspapers, social media, leaflets and posters at the pharmacy. Customers wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health. A HbA1c measurement was performed for individuals with a moderate to high risk of developing diabetes. If HbA1c ≥ 6.5% they were recommended to visit their general practitioner for follow-up. The pharmacies performed internal and external quality control of the HbA1c instrument.

Results: Of the 211 included participants 97 (46%) were > 50 years old. HbA1c was measured for the 47 participants (22%) with high risk. Thirty-two (15%) had HbA1c values < 5.7%, twelve (5.4%) had values between 5.7%-6.4%, and three (1.4%) had an HbA1c ≥ 6.5%. Two participants with HbA1 ≥ 6.5% were diagnosed with diabetes by their general practitioner. The third was lost to follow-up. Results from internal and external quality control for HbA1c were within set limits.

Conclusion: The pharmacists were able to perform the risk assessment and measurement of HbA1c, and pharmacy customers were willing to participate. The HbA1c measurements fulfilled the requirements for analytical quality. Thus, it is feasible to implement this service in community pharmacies in Norway. In a large-scale study the inclusion criteria should be increased to 45 years in accordance with the population the risk test has been validated for.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Community Pharmacy Services
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / diagnosis*
  • Feasibility Studies
  • Female
  • Glycated Hemoglobin / analysis*
  • Glycated Hemoglobin / standards
  • Humans
  • Male
  • Mass Screening / methods
  • Middle Aged
  • Norway
  • Pharmacies
  • Quality Control
  • Risk Assessment
  • Surveys and Questionnaires

Substances

  • Glycated Hemoglobin A
  • hemoglobin A1c protein, human

Grants and funding

The study was financed by The Norwegian Community Pharmacy Foundation (https://www.proff.no/selskap/stiftelsen-til-fremme-av-norskapotekfarmasi/oslo/fondlegat/IG9KD0M10NC/) and the University of Bergen (http://www.uib.no). The purpose of the Norwegian Community Pharmacy Foundation is to help promote the development of Norwegian pharmacy. Siemens (https://www.siemens.com/no/no/home.html) lent the DCA Vantage Analyzer instruments to the pharmacies and provided training free of charge. The participating pharmacy chain, Apotek 1, covered expenses of the course day and paid the membership fee in Noklus. The Norwegian Community Pharmacy Foundation had no influence on how the study was conducted, the analysis or the results. Apotek 1, University of Bergen, Siemens and The Norwegian Community Pharmacy Foundation had no influence on the analysis or the results, but Apotek 1 have been given valuable input to the protocol and procedures.